EM2411F "From Mystery to Mastery: Game-Changing Tools for Low-Risk MDS" (IM GR -111524)

Purpose and Overview

Myelodysplastic syndromes are clonal stem-cell disorders that lead to ineffective hematopoiesis and carry the risk of progression to acute myeloid leukemia. Anemia is the most common cytopenia in patients with lower-risk myelodysplastic syndromes. The progression of this anemia leads to transfusion dependence and detriment to the patient's quality of life due to clinical symptoms and the multiple health-care interactions required to maintain a suitable concentration of hemoglobin. Few options exist that target anemia in patients with lower-risk myelodysplastic syndromes. Advances have been made over the past few years with new drug approvals for patients with lower-risk MDS which improve hemoglobin levels and lead to transfusion independence for patients with lower-risk MDS.

Target Audience

UT Southwestern faculty, fellows, residents and medical students, community physicians, nurse clinicians, physician assistants and nurses.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

  • Identify when to suspect a diagnosis of myelodysplastic syndrome (MDS)
  • Recognize differences in the management approach for patients with lower- vs higher-risk (MDS)
  • Recognize newly approved therapies for patients with lower-risk MDS
Course summary
Available credit: 
  • 1.00 AMA
Course opens: 
11/19/2024
Course expires: 
12/19/2024
Cost:
$0.00
Rating: 
0

Photo: First Last, M.D.
Yazan F. Madanat, M.D.
Associate Professor of Internal Medicine
Division of Hematology & Oncology

Available Credit

  • 1.00 AMA

Price

Cost:
$0.00
Please login or create an account to take this course.

Required Hardware/software

Activities should be run with recent versions of common browsers, including Internet Explorer, Firefox and Google Chrome